Find out why possibility lives at Bristol Myers Squibb, We demonstrate ethics, integrity and quality in everything we do for patients, customers and colleagues, We pursue disruptive and bold solutions for patients, We move together with speed and quality because patients are waiting, Our dedication to learning and excellence helps us to deliver exceptional results, We all own BMS success and strive to be transparent and deliver on our commitments, We embrace diversity and foster an environment where we can all work together at our full potential. The recognition is a testament to our commitment to transform patients lives through science. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. 0000015083 00000 n customer.relations@bms.com (877) 517-6326 (Monday-Friday, 8 AM-8 PM ET) Adverse event or product quality complaints (800) 721-5072 Returns Potential A 15% price target upside from sell-side analysts. "The first of the new aircraft will enter service in late-2023, with the bulk to . Learn about our safety approach to COVID-19 > At Bristol Myers Squibb, the work you do-often in support of emerging therapeutic areas that require new methods of thinking and working-will help people prevail over serious diseases. Connect with a more experienced colleague to be your sounding board and to help guide you forward. Join scientists like Aparna's team, who have helped Bristol Myers Squibb establish a leadership position within hematology oncology therapies, doing interesting and meaningful work while transforming patients lives daily. More information on suppliers is available here. schedule conferences . Non-GAAP earnings and related EPS information are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. None of our operations have been identified as having significant risk for incidents of child labor or forced labor. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. Insights for Success: We are committed to creating an inclusive environment and have invested in training for woman and underrepresented groups. ** Included as part of the new product portfolio The company continues to maintain a consistent, balanced approach to capital allocation focused on prioritizing investment for growth through business development along with reducing debt, commitment to dividend growth and share repurchase. Your response will be removed from the review this cannot be undone. xref 0000009073 00000 n Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates. This was driven by its aforementioned revenue growth, a 330-basis-point. Accordingly, investors should monitor the Investors section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. In discussing financial results and guidance, the company refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). LICENSE AGREEMENT. Whether its bringing more than a dozen key medicines to market since 2009, or expanding patient access to medicine, our commitment to patients inspires us and guides our actions as responsible corporate citizens. The study was conducted by The Bristol Myers Squibb-Janssen Collaboration. Learn about our safety approach to COVID-19 > At Bristol Myers Squibb, the work you do-often in support of emerging therapeutic areas that require new methods of thinking and working-will help people prevail over serious diseases. Source: Bristol-Myers Squibb The transaction is the biggest acquisition ever announced so early in a calendar year, according to data compiled by Bloomberg going back to 1990. Both GAAP and non-GAAP guidance assume current exchange rates. 866 0 obj Employees must meet all eligibility requirements in order to qualify. Acquisition Brings Repotrectinib, a Potential Best-in-Class, Next-Generation ROS1/NTRK Inhibitor with Differentiated Duration of Response for Patients with ROS1-positive First-Line Non-Small Cell Lung Cancer; Expected to Launch in 2023, Bristol Myers Squibb to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Turning Point Therapeutics for $76.00 per Share, Expected to be Accretive to Non-GAAP Earnings Per Share beginning in 2025. Operating expenses, consisting of marketing, selling and administrative expenses and research and development expenses, are expected to decrease by approximately 10% for GAAP and be in-line with 2021 levels for non-GAAP. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Whether it's bringing key medicines to market, or expanding patient access to medicines, our commitment to patients drives innovation in our pipeline and guides our action as a responsible corporate citizen. Bristol-Myers is Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: 21-04897. 0000042754 00000 n 3 floating holidays. 0000014201 00000 n UA System. Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said.. Bristol-Myers shares have gained 6.4% year to date against the industry's decline of 1.3%.. Top Key Vendor's likes - Boehringer Ingelheim, Bristol-Myers Squibb Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. These statements may be identified by the fact they use words such as should, could, expect, anticipate, estimate, target, may, project, guidance, intend, plan, believe, will and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. The tender offer described in this communication has not yet commenced. Jewish Calendar 2021 Tuusula, Uusimaa, Finland. Expects low- to mid-single digit revenue CAGR and low double-digit revenue CAGR for our Continuing Business, Expects to maintain low- to mid-40s percent non-GAAP operating margin, Expects significant free cash flow generation of $45-$50 billion dollars from 2022-2024. The companys pipeline of precision oncology drug candidates is being studied across a variety of solid tumors. They merged in 1989, creating a powerhouse pharmaceutical company that was the second-largest in the world at the time. Bristol-Myers confirmed that it had signed a deal to develop Agenus antibody treatment known as AGEN1777. Air India, part of Tata group, had signed an order for 40 GE engines, plus a multi-year engine services agreement. (link). though we are required to work bank holidays, Paid holidays for employees are always offered, they add weeks off at times. %PDF-1.5 % Gordon Dyal & Co., LLC is serving as the exclusive financial advisor to Bristol Myers Squibb, and Kirkland & Ellis LLP is serving as legal counsel. People and Business Resource Groups are provided mentor/mentee learning and development among employees on a global scale. If, like us, you believe in the power of science to address some of the most challenging diseases of our time, then youll fit right in as we search for the next breakthroughs in biopharma. Yield Attractiveness B 3.27% forward dividend yield. When you join one of our diverse, high-achieving teams, youll collaborate each day to help transform the lives of patients around the world. A dds details on agreement, background. **Included as part of the new product portfolio 0000003347 00000 n Upcoming events. The actual financial impact of this transaction may differ from the expected financial impact described in this communication. BMS Benefits and Work Life. The accounting treatment as a business combination or asset acquisition will be determined upon the expected close of the transaction in the third quarter of 2022. Materials on this website may contain information about the Company's future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. 0000008533 00000 n Learn about joining our global team! Print. We routinely post important information for investors on our website, BMS.com, in the Investors section. They offer 3 weeks after 3 or 4 years and they go up every couple of years. 867 0 obj (( g Bristol Myers Squibb will not tolerate practices that violate the intent of our Mission and Commitment. Income tax benefit was approximately $510 million despite pre-tax earnings of $1.9 billion in the quarter primarily due to the impact of internal transfers of certain intangible assets of $1.0 billion. Play. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events or otherwise. Analysts estimate that Bristol-Myers Squibb will report an earnings per share (EPS) of $1.72. 0000002307 00000 n Top 50%. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item. Returns Risk A+ 0.4 beta (5Y monthly). Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the companys website at www.bms.com., Risk Evaluation and Mitigation Strategies (REMS), Pre-Approval Access to Investigational Medicines, Areas of Interest & Competitive Research Grants, The Thomas O. Daniel Research Incubator and Collaboration Center, Acquisition FAQs for Celgene Shareholders, Acquisition-related information for Celgene shareholders, Unsubscribe to News Email Alerts - Bristol Myers Squibb, Subscribe to New Email Alerts - Bristol Myers Squibb, BMS at June 2022 oncology and hematology congresses, Committed to creating a better future for cancer patients, People & Business Resource Groups leadership team, Our Commitment to Equal Employment Opportunity, Access to Medicines in the Developing World, UK-CA Slavery and Human Trafficking Statement (PDF), Our Commitment to Global Inclusion & Diversity>. It offers chemically-synthesized drugs or. These documents will be available at no charge on the SECs website at www.sec.gov. Also note that a reconciliation of the forward-looking revenue (ex-FX), free cash flow and non-GAAP operating margin measures is not provided due to the inherent difficulty in forecasting and quantifying items that are necessary for such reconciliation. Every year, key managers and executives are required to certify that they have read, understand, are in compliance with, and will continue to comply with our Standards of Business Conduct and Ethics. The performance of key suppliers is monitored regularly. Our Continuing Business, which represents in-line products and new product portfolio, is expected to grow in the low-double digits and contribute approximately $36.5 billion in 2022. We incorporate security and human rights in our assessment of countries when determining where to locate operating facilities. There's been plenty of good news for Bristol Myers Squibb (BMY 0.13%) . We know its not easy to make a difference, so we make sure each employee feels empowered and motivated in their efforts to do so. ET during which company executives will review financial information and address inquiries from investors and analysts. Join scientists like Aparna's team, who have helped Bristol Myers Squibb establish a leadership position within hematology oncology therapies, doing interesting and meaningful work while transforming patients lives daily. International revenues increased 4% to $4.5 billion in the quarter. In addition, the compounds described in this communication are subject to all the risks inherent in the drug development process, and there can be no assurance that the development of these compounds will be commercially successful. 0000004547 00000 n Available to US-based employeesChange location, Comparable to many others in the same league. Here we feature several BMS colleagues sharing their views on the subject from their perspectives, based on their own experiences. A cash dividend payment of $0.49 per share is scheduled to be paid on November 01, 2021. (, In December, the company announced that its Board of Directors approved an increase in the quarterly dividend and authorized an additional $15 billion, multi-year share repurchase program. In addition to the items discussed above, the results in the same period a year ago included an IPR&D charge related to the MyoKardia asset acquisition of $11.4 billion and the impact of fair value adjustments on equity investments and contingent value rights in both periods. These statements are only predictions, and such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Under the terms of the merger agreement, Bristol Myers Squibb will promptly commence a tender offer to acquire all of the outstanding shares of Turning Point Therapeutics common stock at a price of $76.00 per share in an all-cash transaction for a total consideration of $4.1 billion in equity value. NEW YORK--(BUSINESS WIRE)-- Special . Recently declared a week off fro everybody between xmas and new years. There are regular US holidays with 4 floating holiday/personal days. 0000008372 00000 n (. Available to US-based employeesChange location. All comparisons are made versus the same period in 2020 unless otherwise stated. paid time off and holidays- employees are expected to work holidays at times. Worldwide revenues are expected to be approximately $47 billion, representing an increase in the low-single digits. For more information, visit www.tptherapeutics.com. Total Rewards may differ based on country; the benefits described on this site are specific to those in the U.S. Breakout Session - Bristol Myers Squibb Presents: The Future of Cancer Care: Transformative Innovation for All . Home; Our Services; About us; Blog; Contact They encouraged employees to take their vacations. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram. Stocks gain as Bostic backs quarter-point hike; Hewlett Packard Enterprise lifts annual guidance after Q1 results beat estimates; Fed wrestles whether recent data a 'blip' or a warning on inflation Monday Jan 11, 2021 07:30 AM ET. Play. No forward-looking statement can be guaranteed. Bristol-Myers Squibb is a multinational pharmaceutical company headquartered in New York City. Media: media@bms.com Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share. Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the 2021 Bank of America Securities Virtual Health Care Conference, which will be webcast on Tuesday, May 11, 2021. The case is UMB Bank NA v Bristol-Myers Squibb (NYSE: BMY) Co et al, U.S. District Court, Southern District of New York, No. Learn about Bristol Myers Squibb Vacation & Paid Time Off, including a description from the employer, and comments and ratings provided anonymously by current and former Bristol Myers Squibb employees. Compliance with data privacy laws on a global basis is an essential business practice for Bristol Myers Squibb. Show more Show less Resident Advisor Bucknell University . Bristol-Myers Squibb BMY | stock $69.02 0.09% $147 B 3.31% $2.28 - Ratings - BMY Dividend Safety A+ 16 years of consecutive dividend increase. Minor Fasts . 0000043468 00000 n No matter the role within BMS, we all embrace a patient-centric culture. 0000001396 00000 n And while our work transforms the lives of patients, it also transforms the lives and careers of those who do it. Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to or as a substitute for the related financial measures that are prepared in accordance with GAAP and are not intended to be considered in isolation and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. With Bristol Myers Squibbs leadership in oncology, strong commercial capabilities and manufacturing footprint, we will be able to further accelerate the pace at which we can bring our novel medicines to benefit people diagnosed with cancer around the world., Financial Details and 2022 Financial Guidance. Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite InstabilityHigh Metastatic Colorectal Cancer After Prior Chemotherapy. Media and Investor Relations: ir@tptherapeutics.com, Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company. 0000007256 00000 n Normal for industry. 2020; 2022 Calendar Settings. Drug Discovery and Translational Medicine, Equal Employment Opportunity / Disability Assistance. The non-GAAP financial measures are provided as supplemental information to the financial measures presented in this communication that are calculated and presented in accordance with GAAP and are presented because management has evaluated the companys financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the company's baseline performance, supplement or enhance management, analysts and investors overall understanding of the companys underlying financial performance and trends and facilitate comparisons among current, past and future periods. Percentages and earnings per share amounts presented are calculated from the underlying amounts. The company also plans to continue to explore the potential of Turning Point Therapeutics promising pipeline of novel compounds. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. If you have $1,000 at the ready, pharmaceutical stock Bristol Myers Squibb *Stock Advisor returns as of June 7, 2021. Actual results may differ materially from current expectations because of numerous risks and uncertainties including with respect to (i) the timing of the tender offer and the subsequent merger, (ii) the number of shares of the Turning Point Therapeutics common stock that will be tendered in the tender offer, (iii) the risk that the expected benefits or synergies of the acquisition will not be realized, (iv) the risk that legal proceedings may be instituted related to the merger agreement, (v) any competing offers or acquisition proposals for Turning Point Therapeutics, (vi) the possibility that various conditions to the consummation of the tender offer or the acquisition may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the offer or the acquisition and (vii) unanticipated difficulties or expenditures relating to the proposed transaction, the response of business partners and competitors to the announcement of the proposed transaction and/or potential difficulties in employee retention as a result of the announcement and pendency of the proposed transaction. General Manager Development: We partner with the premier CEDEP organization to build our future General Manager talent through this internationally recognized program. A replay of the conference call will be available beginning at 11:30 a.m. The companys performance in the first quarter of 2021 Furthermore, one of the three required milestones for payment of the Bristol Myers Squibb Contingent Value Right (CVR) remained unaccomplished due to the pending FDA approval as of Dec. 31, 2020. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. Additional Information about the Tender Offer and Where to Find it. 2021 was a pivotal year for our company as we achieved significant regulatory and clinical milestones and positioned the company to successfully renew our portfolio. Posted: October 12, 2021 Full-Time At Bristol Myers Squibb, we are inspired by a single vision - transforming patients' lives through science. 0000004307 00000 n Major Holidays. 0000115702 00000 n Case Timeline November 12, 2021 PRESS RELEASE: FTC Approves Modifications to Bristol Meyers Squibb Divestiture Agreement January 13, 2020 File Complaint (112.81 KB) File We may use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. A copy of the tender offer statement and the solicitation/recommendation statement will be made available to all stockholders of Turning Point Therapeutics free of charge at tptherapeutics.com. When adjusted for foreign exchange impact, international revenues increased 7%. Learn about joining our global team! ***Included as part of the key loss of exclusivity (LOE) brands, FOURTH QUARTER PRODUCT AND PIPELINE UPDATE, In December, the company issued its 2021 Global Access Report that detailed Bristol Myers Squibbs efforts and progress towards advancing access to healthcare and health equity globally through its own efforts and in partnership with other stakeholders. though we are required to work bank holidays, Paid holidays for employees are always offered, they add weeks off at times. The information contained on, or that may be accessed through, our website or social media channels are not incorporated by reference into, and are not a part of, this document. ET on February 4 through 11:30 a.m. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Bristol-Myers Squibb has 9 holidays and 4 personal/floating holidays. A REMS program was included in the initial application for mavacamten. None of our operations have been identified as having significant risk for incidents of child labor or forced labor. 0000043721 00000 n The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Shareholders. 0000005253 00000 n July 28 (Reuters) - Bristol Myers Squibb Co (BMY.N) reported second quarter earnings that topped Wall Street estimates, as sales of flagship cancer treatment Opdivo returned to growth after. Learn about Bristol Myers Squibb Paid Holidays, including a description from the employer, and comments and ratings provided anonymously by current and former Bristol Myers Squibb employees. March 01, 2023 09:22 am EST. I am proud of how our company performed in 2021, helping more patients across our therapeutic areas, while achieving 9% revenue and 17% non-GAAP EPS growth, respectively, said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the companys website at www.bms.com . Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com or by using this link which becomes active 15 minutes prior to the scheduled start time and entering your information to be connected. Image Source: Zacks Investment Research. Bristol-Myers Squibb has a 1 year low of $54.07 and a 1 year high of $67.16. These statements are likely to relate to, among other things, the companys ability to execute successfully its strategic plans, including its business development strategy and capital allocation strategy, planned product launches and updates, expectations relating to its pipeline and in relation to its ability to realize the projected benefits of the Celgene acquisition and the MyoKardia acquisition, the full extent of the impact of the COVID-19 pandemic on the companys operations and the development and commercialization of its products, potential laws and regulations to lower drug costs, market actions taken by private and government payers to manage drug utilization and contain costs, the expiration of patents or data protection on certain products, including assumptions about the companys ability to retain patent exclusivity of certain products, and the impact and the result of governmental investigations. I am confident in our ability to execute against our key milestones in 2022, including three planned first-in-class launches with relatlimab plus nivolumab fixed dose combination, mavacamten and deucravacitinib. Required to work every rotating weekends, some holidays, and during adverse weather conditions in support of . Engage with instructors and fellow students for half-day or up to three-day programs in a virtual or classroom setting. Your future colleagues at Bristol Myers Squibb are impacting lives every day. (PDF), UK-CA Slavery and Human Trafficking Statement (PDF), Our Commitment to Global Inclusion & Diversity>. Its good at least for California based employees. Israel holiday schedule. We incent, recognize, reward and celebrate those who consistently embody our mission and behaviors to reach above and beyond, driving our business forward. 0000192949 00000 n Bristol Myers Squibb to Participate in the 39th Annual J.P. Morgan Healthcare Conference testtest test. These statements may be identified by the fact they use words such as should, could, expect, anticipate, estimate, target, may, project, guidance, intend, plan, believe, will and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. <>z{^)P"PPq@ 6/ Bristol Myers (BMY) Earnings Date & Reports 8,681 Followers Portfolio Earnings Data Report Date Apr 27, 2023 Before Open Not Confirmed Period Ending 2023 (Q1) Consensus EPS Forecast $1.98 Last Year's EPS $1.96 Same Quarter Last Year Analyst Consensus Moderate Buy Based on 9 Analysts Ratings Bristol Myers (BMY) Earnings, Revenues Date & History Materials related to the call will be available at the same website prior to the conference call. 11:00 am EST. Diaspora holiday schedule. Events and Presentations. Bristol-Myers in May entered into a $1.56 billion deal with Agenus Inc to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Wednesday, April 28th. Amortization of acquired intangible assets decreased 4% to $2.4 billion in the quarter primarily due to an extended marketed product rights exclusivity period. Such risks, uncertainties and other matters include, but are not limited to: increasing pricing pressures from market access, pharmaceutical pricing controls and discounting; changes to tax and importation laws and other restrictions in the United States, the European Union and other regions around the world that result in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse; changes under the 340B Drug Pricing Program; challenges inherent in new product development, including obtaining and maintaining regulatory approval; the companys ability to obtain and protect market exclusivity rights and enforce patents and other intellectual property rights; the possibility of difficulties and delays in product introduction and commercialization; the risk of certain novel approaches to disease treatment (such as CAR T therapy); industry competition from other manufacturers; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products, including without limitation, interruptions caused by damage to the companys and the companys suppliers manufacturing sites; the impact of integrating the companys and Celgenes business and operations, including with respect to human capital management, portfolio rationalization, finance and accounting systems, sales operations and product distribution, pricing systems and methodologies, data security systems, compliance programs and internal controls processes; the risk of an adverse patent litigation decision or settlement and exposure to other litigation and/or regulatory actions; the impact of any healthcare reform and legislation or regulatory action in the United States and international markets; increasing market penetration of lower-priced generic products; the failure of the companys suppliers, vendors, outsourcing partners, alliance partners and other third parties to meet their contractual, regulatory and other obligations; regulatory decisions impacting labeling, manufacturing processes and/or other matters; the impact on the companys competitive position from counterfeit or unregistered versions of its products or stolen products; the adverse impact of cyber-attacks on the companys information systems or products, including unauthorized disclosure of trade secrets or other confidential data stored in the companys information systems and networks; the companys ability to execute its financial, strategic and operational plans; the companys ability to identify potential strategic acquisitions, licensing opportunities or other beneficial transactions; the companys dependency on several key products; any decline in the companys future royalty streams; the companys ability to effectively manage acquisitions, divestitures, alliances and other portfolio actions and to successfully realize the expected benefits of such actions; the companys ability to attract and retain key personnel; the impact of the companys significant additional indebtedness that it incurred in connection with the Celgene acquisition and the MyoKardia acquisition; political and financial instability of international economies and sovereign risk; interest rate and currency exchange rate fluctuations, credit and foreign exchange risk management; the impact of adverse outcomes in lawsuits, claims, proceedings and government investigations; the impact of our exclusive forum provision in our by-laws for certain lawsuits on our stockholders ability to obtain a judicial forum that it finds favorable for such lawsuits; issuance of new or revised accounting standards; and risks relating to public health outbreaks, epidemics and pandemics, including the impact of the COVID-19 pandemic on the companys operations.

Lead4ward Vertical Alignment, Who Is The Actress In Xiidra Commercial, Margaret Henderson Obituary, Articles B